fenofibrate has been researched along with Weight Loss in 11 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
Weight Loss: Decrease in existing BODY WEIGHT.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In subjects with obesity, diabetes and coronary artery disease, circulating levels of leptin increased while that of adiponectin is decreased." | 7.74 | The effects of physiological and pharmacological weight loss on adiponectin and leptin mRNA levels in the rat epididymal adipose tissue. ( Fatani, S; Hunter, L; Naderali, EK; Telles, M, 2008) |
| " We assessed the effects of rimonabant, alone and in combination with fenofibrate or ezetimibe, on adipokine levels in obese/overweight patients with dyslipidemia." | 5.14 | Effects of rimonabant, as monotherapy and in combination with fenofibrate or ezetimibe, on plasma adipokine levels: a pilot study. ( Derdemezis, CS; Elisaf, M; Florentin, M; Liberopoulos, EN; Tellis, CC; Tselepis, A, 2010) |
| " Fenofibrate, a selective peroxisome proliferator-activated receptor α (PPAR-α) agonist, elicits weight loss in animal models." | 3.81 | PPAR-α agonist elicits metabolically active brown adipocytes and weight loss in diet-induced obese mice. ( Aguila, MB; Bringhenti, I; Mandarim-de-Lacerda, CA; Penna-de-Carvalho, A; Rachid, TL; Souza-Mello, V, 2015) |
| "In subjects with obesity, diabetes and coronary artery disease, circulating levels of leptin increased while that of adiponectin is decreased." | 3.74 | The effects of physiological and pharmacological weight loss on adiponectin and leptin mRNA levels in the rat epididymal adipose tissue. ( Fatani, S; Hunter, L; Naderali, EK; Telles, M, 2008) |
| "The attenuation of diabetic kidney disease (DKD) by metabolic surgery is enhanced by pharmacotherapy promoting renal fatty acid oxidation (FAO)." | 1.72 | Dietary restriction and medical therapy drives PPARα-regulated improvements in early diabetic kidney disease in male rats. ( Abdelaal, M; Abrahamsson, S; Brennan, EP; Chuah, YHD; Docherty, NG; Eckhardt, H; Elliott, JA; Fändriks, L; Fearon, N; Godson, C; Hutter, M; le Roux, CW; Malmodin, D; Martin, WP; Nair, M; Pedersen, A, 2022) |
| "Amiodarone treated PPARα(-/-) mice exhibited significantly greater weight loss and higher serum aspartate aminotransferase (AST) compared to PPARα(+/+) mice." | 1.36 | Influence of peroxisome proliferator-activated receptor-alpha (PPARα) activity on adverse effects associated with amiodarone exposure in mice. ( Ernst, MC; Pollak, PT; Sinal, CJ, 2010) |
| "Fenofibrate treatment markedly increased circulating resistin levels on both diets and adiponectin levels in chow-fed mice only." | 1.33 | Improvement of insulin sensitivity after peroxisome proliferator-activated receptor-alpha agonist treatment is accompanied by paradoxical increase of circulating resistin levels. ( Dolinkova, M; Haluzik, M; Haluzik, MM; Haluzikova, D; Horinek, A; Housa, D; Kumstyrova, T; Lacinova, Z; Vernerova, Z, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Sashidhara, KV | 1 |
| Kumar, M | 1 |
| Sonkar, R | 1 |
| Singh, BS | 1 |
| Khanna, AK | 1 |
| Bhatia, G | 1 |
| Martin, WP | 1 |
| Nair, M | 1 |
| Chuah, YHD | 1 |
| Malmodin, D | 1 |
| Pedersen, A | 1 |
| Abrahamsson, S | 1 |
| Hutter, M | 1 |
| Abdelaal, M | 1 |
| Elliott, JA | 1 |
| Fearon, N | 1 |
| Eckhardt, H | 1 |
| Godson, C | 1 |
| Brennan, EP | 1 |
| Fändriks, L | 1 |
| le Roux, CW | 1 |
| Docherty, NG | 1 |
| Rachid, TL | 1 |
| Penna-de-Carvalho, A | 1 |
| Bringhenti, I | 1 |
| Aguila, MB | 1 |
| Mandarim-de-Lacerda, CA | 1 |
| Souza-Mello, V | 1 |
| Florentin, M | 1 |
| Liberopoulos, EN | 2 |
| Tellis, CC | 1 |
| Derdemezis, CS | 1 |
| Elisaf, M | 1 |
| Tselepis, A | 1 |
| Ernst, MC | 1 |
| Sinal, CJ | 1 |
| Pollak, PT | 1 |
| Vikramadithyan, RK | 1 |
| Hiriyan, J | 1 |
| Suresh, J | 1 |
| Gershome, C | 1 |
| Babu, RK | 1 |
| Misra, P | 1 |
| Rajagopalan, R | 1 |
| Chakrabarti, R | 1 |
| Iglesias, P | 1 |
| Alvarez Fidalgo, P | 1 |
| Codoceo, R | 1 |
| Díez, JJ | 1 |
| Athyros, VG | 1 |
| Mikhailidis, DP | 1 |
| Didangelos, TP | 1 |
| Giouleme, OI | 1 |
| Karagiannis, A | 1 |
| Kakafika, AI | 1 |
| Tziomalos, K | 1 |
| Burroughs, AK | 1 |
| Elisaf, MS | 1 |
| Haluzik, MM | 1 |
| Lacinova, Z | 1 |
| Dolinkova, M | 1 |
| Haluzikova, D | 1 |
| Housa, D | 1 |
| Horinek, A | 1 |
| Vernerova, Z | 1 |
| Kumstyrova, T | 1 |
| Haluzik, M | 1 |
| Naderali, EK | 1 |
| Fatani, S | 1 |
| Telles, M | 1 |
| Hunter, L | 1 |
| Muls, E | 1 |
| Van Gaal, L | 1 |
| Autier, P | 1 |
| Vansant, G | 1 |
2 trials available for fenofibrate and Weight Loss
| Article | Year |
|---|---|
Effects of rimonabant, as monotherapy and in combination with fenofibrate or ezetimibe, on plasma adipokine levels: a pilot study.
Topics: Adipokines; Adult; Aged; Azetidines; Body Mass Index; Diet, Reducing; Drug Therapy, Combination; Dys | 2010 |
Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study.
Topics: Anti-Obesity Agents; Atorvastatin; Diet, Fat-Restricted; Drug Therapy, Combination; Dyslipidemias; F | 2006 |
9 other studies available for fenofibrate and Weight Loss
| Article | Year |
|---|---|
Indole-based fibrates as potential hypolipidemic and antiobesity agents.
Topics: Animals; Anti-Obesity Agents; Bile Acids and Salts; Butyrates; Dietary Fats; Fatty Liver; Feces; Fee | 2012 |
Dietary restriction and medical therapy drives PPARα-regulated improvements in early diabetic kidney disease in male rats.
Topics: Animals; Diabetes Mellitus; Diabetic Nephropathies; Fenofibrate; Kidney; Male; Niacinamide; PPAR alp | 2022 |
PPAR-α agonist elicits metabolically active brown adipocytes and weight loss in diet-induced obese mice.
Topics: Adipocytes, Brown; Adipose Tissue; Animals; Biomarkers; Diet; Energy Metabolism; Fenofibrate; Hypoli | 2015 |
Influence of peroxisome proliferator-activated receptor-alpha (PPARα) activity on adverse effects associated with amiodarone exposure in mice.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Aspartate Aminotransferases; Dose-Response Relationship | 2010 |
DRF 2655: a unique molecule that reduces body weight and ameliorates metabolic abnormalities.
Topics: 3T3 Cells; Adipocytes; Animals; Anti-Obesity Agents; Cell Differentiation; Cell Line; Cholesterol; C | 2003 |
Lipoatrophic diabetes in an elderly woman: clinical course and serum adipocytokine concentrations.
Topics: Adiponectin; Aged; Blood Glucose; Cytokines; Diabetes Mellitus, Lipoatrophic; Diabetes Mellitus, Typ | 2004 |
Improvement of insulin sensitivity after peroxisome proliferator-activated receptor-alpha agonist treatment is accompanied by paradoxical increase of circulating resistin levels.
Topics: Adiponectin; Adipose Tissue; Animals; Blood Glucose; Diet; Dietary Carbohydrates; Fatty Acids, Nones | 2006 |
The effects of physiological and pharmacological weight loss on adiponectin and leptin mRNA levels in the rat epididymal adipose tissue.
Topics: Adiponectin; Adipose Tissue; Animals; Epididymis; Fatty Acids, Nonesterified; Fenofibrate; Gene Expr | 2008 |
Effects of initial BMI and on-treatment weight change on the lipid-lowering efficacy of fibrates.
Topics: Body Mass Index; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypercholes | 1997 |